JP2018531995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531995A5 JP2018531995A5 JP2018538936A JP2018538936A JP2018531995A5 JP 2018531995 A5 JP2018531995 A5 JP 2018531995A5 JP 2018538936 A JP2018538936 A JP 2018538936A JP 2018538936 A JP2018538936 A JP 2018538936A JP 2018531995 A5 JP2018531995 A5 JP 2018531995A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- subject
- cancer
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000011502 immune monitoring Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306650 | 2015-10-15 | ||
| EP15306650.1 | 2015-10-15 | ||
| PCT/EP2016/074682 WO2017064241A1 (en) | 2015-10-15 | 2016-10-14 | Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531995A JP2018531995A (ja) | 2018-11-01 |
| JP2018531995A5 true JP2018531995A5 (enExample) | 2019-10-24 |
| JP7062592B2 JP7062592B2 (ja) | 2022-05-06 |
Family
ID=54360386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538936A Active JP7062592B2 (ja) | 2015-10-15 | 2016-10-14 | アミノチオールエステル化合物またはその薬学的に許容される塩および対象の癌細胞におけるｈ２ｏ２濃度を増大し得る化合物の組み合わせ |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10406125B2 (enExample) |
| EP (1) | EP3362094B1 (enExample) |
| JP (1) | JP7062592B2 (enExample) |
| CN (1) | CN108348612A (enExample) |
| AR (1) | AR106351A1 (enExample) |
| CA (1) | CA3001201C (enExample) |
| CY (1) | CY1123916T1 (enExample) |
| DK (1) | DK3362094T3 (enExample) |
| ES (1) | ES2870508T3 (enExample) |
| HR (1) | HRP20210358T1 (enExample) |
| HU (1) | HUE054247T2 (enExample) |
| IL (1) | IL258658B (enExample) |
| LT (1) | LT3362094T (enExample) |
| MX (1) | MX377725B (enExample) |
| PL (1) | PL3362094T3 (enExample) |
| PT (1) | PT3362094T (enExample) |
| RS (1) | RS61572B1 (enExample) |
| SI (1) | SI3362094T1 (enExample) |
| SM (1) | SMT202100270T1 (enExample) |
| WO (1) | WO2017064241A1 (enExample) |
| ZA (1) | ZA201802400B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3833657T (pt) * | 2019-07-31 | 2022-09-28 | Advanced Biodesign | Compostos de aminotiolester e seus usos |
| EP4035666A1 (en) * | 2021-01-29 | 2022-08-03 | Advanced Biodesign | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent |
| FR3119314B1 (fr) * | 2021-01-29 | 2025-01-10 | Advanced Biodesign | Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable |
| WO2025229179A1 (en) * | 2024-05-03 | 2025-11-06 | Advanced Biodesign | Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777001B1 (fr) * | 1998-04-01 | 2000-06-09 | Cird Galderma | Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses |
| FR2809727B1 (fr) * | 2000-05-31 | 2002-07-26 | Galderma Res & Dev | Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
-
2016
- 2016-10-14 HR HRP20210358TT patent/HRP20210358T1/hr unknown
- 2016-10-14 RS RS20210309A patent/RS61572B1/sr unknown
- 2016-10-14 HU HUE16784442A patent/HUE054247T2/hu unknown
- 2016-10-14 ES ES16784442T patent/ES2870508T3/es active Active
- 2016-10-14 LT LTEP16784442.2T patent/LT3362094T/lt unknown
- 2016-10-14 SM SM20210270T patent/SMT202100270T1/it unknown
- 2016-10-14 PT PT167844422T patent/PT3362094T/pt unknown
- 2016-10-14 PL PL16784442T patent/PL3362094T3/pl unknown
- 2016-10-14 MX MX2018004381A patent/MX377725B/es active IP Right Grant
- 2016-10-14 WO PCT/EP2016/074682 patent/WO2017064241A1/en not_active Ceased
- 2016-10-14 CA CA3001201A patent/CA3001201C/en active Active
- 2016-10-14 JP JP2018538936A patent/JP7062592B2/ja active Active
- 2016-10-14 US US15/768,468 patent/US10406125B2/en active Active
- 2016-10-14 DK DK16784442.2T patent/DK3362094T3/da active
- 2016-10-14 CN CN201680066560.4A patent/CN108348612A/zh active Pending
- 2016-10-14 SI SI201631109T patent/SI3362094T1/sl unknown
- 2016-10-14 EP EP16784442.2A patent/EP3362094B1/en active Active
- 2016-10-14 AR ARP160103143A patent/AR106351A1/es unknown
-
2018
- 2018-04-12 IL IL258658A patent/IL258658B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02400A patent/ZA201802400B/en unknown
-
2021
- 2021-03-02 CY CY20211100174T patent/CY1123916T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090553A1 (ru) | Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| JP2013010792A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2019014758A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2018531995A5 (enExample) | ||
| EA201691142A1 (ru) | Ингибиторы мек и способы их применения | |
| JP2018526413A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016538257A5 (enExample) | ||
| JP2017502967A5 (enExample) | ||
| JP2016516699A5 (enExample) | ||
| EA201690328A1 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
| JP2018524403A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2016505621A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2017511377A5 (enExample) | ||
| JP2017513908A5 (enExample) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |